Patent ID: 8840886

Claim:
A method of reducing an amount of a chemotherapeutic agent necessary to achieve a therapeutic effect in a subject having a cancer or tumor, comprising administering to the subject the chemotherapeutic agent in combination with an antibody or antigen-binding fragment thereof that specifically binds to human Delta-like ligand 4 (hDll4), wherein the antibody or antigen-binding fragment comprises a heavy chain variable region (HCVR) comprising heavy chain CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:22, 24 and 26, respectively, and a light chain variable region (LCVR comprising light chain CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NO:30, 32 and 34, respectively, and wherein the amount of the chemotherapeutic agent is reduced compared to the amount required for the same therapeutic effect in the absence of the antibody or antigen-binding fragment.